Paper11325232
Schizanrins [corrected] B, C, D, and E, four new lignans from Kadsura matsudai and their antihepatitis activities.
Kuo YH and 5 others. J Nat Prod, 2001. Cited by 50 papers, by iCite.
Cite this record
ConductScience Library. Schizanrins [corrected] B, C, D, and E, four new lignans from Kadsura matsudai and their antihepatitis activities. Papers, record 11325232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11325232
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Schizanrins [corrected] B, C, D, and E, four new lignans from Kadsura matsudai and their antihepatitis activities.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Hepatovirus | Major topic |
| Lignans | Major topic |
| Magnoliopsida | Major topic |
| Cell Line | |
| HIV | |
| Microbial Sensitivity Tests | |
| Molecular Structure | |
| Structure-Activity Relationship | |
| Virus Replication |
Source PubMed
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 35564239 | Bioactive Based Nanocarriers for the Treatment of Viral Infections and SARS-CoV-2. | Nanomaterials (Basel) | 2022 | https://conductscience.org/library/papers/35564239 | PubMed |
| 35552885 | Lignans and sesquiterpenoids from the stems of Schisandra bicolor var. tuberculate. | Nat Prod Bioprospect | 2022 | https://conductscience.org/library/papers/35552885 | PubMed |
| 34202844 | A Brief Overview of Potential Treatments for Viral Diseases Using Natural Plant Compounds: The Case of SARS-Cov. | Molecules | 2021 | https://conductscience.org/library/papers/34202844 | PubMed |
| 34093097 | Plant-derived lignans as potential antiviral agents: a systematic review. | Phytochem Rev | 2022 | https://conductscience.org/library/papers/34093097 | PubMed |
| 33234268 | Emerging paradigms of viral diseases and paramount role of natural resources as antiviral agents. | Sci Total Environ | 2021 | https://conductscience.org/library/papers/33234268 | PubMed |
| 24955298 | Panaxadiol and panaxatriol derivatives as anti-hepatitis B virus inhibitors. | Nat Prod Bioprospect | 2014 | https://conductscience.org/library/papers/24955298 | PubMed |
| 23429345 | Neglschisandrins E-F: two new lignans and related cytotoxic lignans from Schisandra neglecta. | Molecules | 2013 | https://conductscience.org/library/papers/23429345 | PubMed |
| 23322017 | Depigmentation effect of kadsuralignan F on melan-a murine melanocytes and human skin equivalents. | Int J Mol Sci | 2013 | https://conductscience.org/library/papers/23322017 | PubMed |
| 23153834 | Traditional Chinese herbal medicine as a source of molecules with antiviral activity. | Antiviral Res | 2013 | https://conductscience.org/library/papers/23153834 | PubMed |
| 21528904 | Ni-catalyzed ketene cycloaddition: a system that resists the formation of decarbonylation side products. | J Am Chem Soc | 2011 | https://conductscience.org/library/papers/21528904 | PubMed |
| 20811804 | The synergism of natural compounds in the pursuit of safe and healthier food. | J Ind Microbiol Biotechnol | 2011 | https://conductscience.org/library/papers/20811804 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11325232
GET https://conductscience.org/api/papers/v1/11325232/authors